Abstract 2144
Background
The Z0011 trial indicated that the information achieved by axillary dissecting lymph nodes (Ax LNs) does not change the prognosis of the disease for patients with clinical node negative breast cancer. Several clinical trials conduct the need for SNB in cases with negative ultrasound-guided (US) fine needle aspiration cytology (FNA) of the suspicious LNs. The aim of this study was to evaluate the reliability of CNB to detect positive LN compared to that of FNA.
Methods
A total of 1465 consecutive patients (pts) with breast cancer were prospectively identified at our institution between March, 2012 and April, 2016. The inclusion criteria of both FNA(21G) and CNB(16G) was cortical thickness greater than 3 mm or abnormal morphologic characteristics. Patients with biopsy-proved metastasis underwent Ax, and those with a negative FNA or CNB underwent SNB. If the SNB was positive, Ax was performed. Diagnostic accuracy was calculated for FNA and CNB.
Results
The number of negative US of LNs was 744 pts, 440 FNA and 212 CNB were performed for suspicious LNs. Sensitivity, specificity, PPV, NPV, and accuracy were 83%, 99%, 97%, 88%, and 91% in FNA, and 93%, 99%, 99%, 97% and 97% in CNB, respectively. SNB was performed in 141 of 212 CNB and 254 of 463 FNA. 141CNB (T1;83,T2;52,T3;9 pts) treated with SNB were compared to 254 FNA (T1;127, T2;116,T3;11 pts) regarding the number of LNs metastasis. The number of positive SLNs and positive LNs more than 3 was 5 (4%), 0(0%) in CNB, and 35(14%), 15(6%) in FNA, respectively.
Conclusions
CNB is a reliable method for the preoperative diagnosis of LNs metastasis. If CNB shows negative LNs, SNB might be safely omitted for patients with breast cancer.
Clinical trial identification
none
Legal entity responsible for the study
N/A
Funding
Chiba Cancer Center
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
Ultra-rapid, sensitive, and fully automated extended RAS testing for metastatic colorectal cancer – evaluation of an NRAS/BRAF/EGFR492 module
Presenter: Ellen Vercauteren
Session: Poster display
Resources:
Abstract
UK phase IV, observational study to assess quality of life in patients (pts) with pancreatic neuroendocrine tumours (pNETS) receiving treatment with everolimus: The “real-world” OBLIQUE study
Presenter: John Ramage
Session: Poster Display
Resources:
Abstract
Tyrosine kinase inhibitors targeted therapy and the AKT-m-TOR pathway in kidney cancer tissues
Presenter: Liudmila Spirina
Session: Poster display
Resources:
Abstract
Tyrosine kinase inhibitors alone as a first-line treatment for patients with non-small-cell lung cancer harboring mutant epidermal growth factor receptor
Presenter: Toshihiko Iuchi
Session: Poster Display
Resources:
Abstract
Typing of non-small cell lung carcinoma and investigation of enteric differentiation in small biopsy specimens
Presenter: aYŞEGÜL Erol
Session: Poster display
Resources:
Abstract
Tumor-infiltrating lymphocytes (TILs) density as prognostic determinant in stage II colorectal cancer
Presenter: Cristiana Lo Nigro
Session: Poster Display
Resources:
Abstract
Tumor response from phase II study of combination treatment with intratumoral HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab in patients with stage IIIB, IIIC, or IV unresectable or metastatic melanoma
Presenter: Robert Andtbacka
Session: Poster display
Resources:
Abstract
Tumor mutation load assessed by FoundationOne (FM1) is associated with improved efficacy of atezolizumab (atezo) in patients with advanced NSCLC
Presenter: Marcin Kowanetz
Session: Poster display
Resources:
Abstract
Tumor lymphocyte infiltrations decrease the risk of late relapse in breast cancer patients
Presenter: Cvetka Grasic Kuhar
Session: Poster display
Resources:
Abstract
Tumor infiltrating lymphocytes and tertiary lymphoid structures in paired primary tumors and metastases from breast cancer patients
Presenter: Cinzia Solinas
Session: Poster display
Resources:
Abstract